Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NVLMTFdjS2WubDDWbYFjcWyrdImgRZN{[Xl? MkXmNE0xNjVizszN MmTUNlQhcA>? NFLQd3dl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NE\WSZgzPTZ4M{e2PS=>
HepG2-HBV1.1 NYK4Wo51SXCxcITvd4l{KEG|c3H5 M{PJPVAuOC53IN88US=> NXLU[ZNHOjRiaB?= MWTpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NFe1NlYzPTZ4M{e2PS=>
HepG2.2.15 MYrGeY5kfGmxbjDBd5NigQ>? M2TVUVAvOSEQvF2= NF7qRpozPCCq MX7wdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= M1q5VFI2PjZ|N{[5
HepG2-HBV1.1 MlTBSpVv[3Srb36gRZN{[Xl? NXXoU3hbOC5zIN88US=> MkLWNlQhcA>? M4HxVZBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> NHTtUVYzPTZ4M{e2PS=>
HepG2-HBV1.1 M1vIOmZ2dmO2aX;uJGF{e2G7 NUfSWZlyOC5zIN88US=> NXXTO4VbPDhiaB?= MlnpdJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ MVyyOVY3Ozd4OR?=
HepG2-HBV1.1 M1XlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvqNE4yKM7:TR?= NGK0WYkyNTViZB?= M3;ne4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= MmnjNlU3PjN5Nkm=
HepG2-HBV1.1 NYLwcldjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\aN2dMOC5zIN88US=> NWjSUIF[OS13IHS= NF\jTGZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 MlXrNlU3PjN5Nkm=
HepG2-HBV1.1 NUPLZ4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\1fpYxNjFizszN NGn3Z5MyOi15MjDo MnzEbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl NX;ofZVtOjV4NkO3Olk>
HepG2-HBV1.1 NWrJOIJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PHOFAvOSEQvF2= MnjINVIuPzJiaB?= NFvERmJqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> Mom2NlU3PjN5Nkm=
Raji M{\jcWZ2dmO2aX;uJGF{e2G7 MkHsNE42yqEQvF2= M1PiVVczKGh? NVr5RVJb[WKxbHnzbIV{KGG3dH;wbIFogcLi NFTmW2EzPTR2NkO3Oy=>
SK-MEL-28  MYTGeY5kfGmxbjDBd5NigQ>? NVjvWWJlOzBibl2= MnW0OkBp MYPpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? NFLDdWszPTNzM{CxNC=>
H157 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LQeGlEPTB;MT6wN{DDuSByLkC0JI1qfTKP MWKyOVI2PzlzMR?=
Jurkat Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnixNU0{KG6P MV20POKhcA>? MV3EUXNQ M{PYToRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MlnNNlUyPTZzNE[=
CEM MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:0NU0{KG6P MUS0POKhcA>? NVXh[WNQTE2VTx?= Mnfn[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> MkDyNlUyPTZzNE[=
P12 NVTYV2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W5WFEuOyCwTR?= M{\HRlQ5yqCq M3HXVmROW09? MmHB[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> M3exZlI2OTV4MUS2
KB NFnafW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEC0PUDDuSByLkCwNFEh|ryP NI\YelAzPTB3OEWyOi=>
KBv200 (ABCB1) MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXWfFVXUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> Ml;QNlUxPTh3Mk[=
SUDHL6  NHHXXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\BcVHjiIoQvF2= Mom5OFgwPzJiaB?= MVHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC|aXfubYZq[2GwdHz5 M4TUfVI1QTZzNkC0
SUDHL6  MVrGeY5kfGmxbjDBd5NigQ>? NULZWYE{OeLCid88US=> NVzweY9JPzJiaB?= MVvpcoR2[2W|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C Mk\1NlQ6PjF4MES=
HCT-116 NXTQXVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV24TpN5T0l3ME21JI5O NVPCfmdjOjR7Mke4OVc>
SKNBe2C M2jzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPiTWM2OD1|Mj64xtE1NjBibl2= MYGyOFkzOTl{MB?=
IGNR91 NFGyUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXxTWM2OD1{ND6zxtEyNjdibl2= NFGyVZEzPDl{MUmyNC=>
SKNAS MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPHTWM2OD1zLkZCtVAvOiCwTR?= NXHQOIt2OjR7MkG5NlA>
LAN1 NYTtNYxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnmTWM2OD1{LkRCtVAvOiCwTR?= NYexR3M6OjR7MkG5NlA>
SHSY5Y NHLxe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThwMtMxNE43KG6P M{DhblI1QTJzOUKw
A549-WT MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7sVJhKSzVyPUG5MlQ{PyEEsTCwMlU6PCBibl2= MXGyOFg2QDh{Nx?=
A549-R NVfpc3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7EbWN5UUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N MW[yOFg2QDh{Nx?=
MCF-7-WT NHvTSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnTOFd5UUN3ME2xO{44PTJiwsGgNE4zOThiIH7N NXH6Z3dQOjR6NUi4Nlc>
MCF-7-R MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rmdWlEPTB;NT61N|khyrFiMD6xOFQhKG6P M4nEcVI1QDV6OEK3
A549-R MmLWR5l1d3SxeHnjbZR6KEG|c3H5 NEH4N5pKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?= M4\zdFI1QDV6OEK3
MCF-7-R M17ibWN6fG:2b4jpZ4l1gSCDc4PhfS=> NV;2XJJnUUN3ME21MlU{QSEEsTCwMlE1PCCwTR?= M37CeFI1QDV6OEK3
SW620 NXjJR3dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTdwOECgxtEhOC5yODDuUS=> NYC4N21qOjR5Mk[3N|k>
SW620/AD300 M2\ZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jXO2lEPTB;OUC5MlYxKMLzIEiuPVEhdk1? MnfINlQ4OjZ5M{m=
HEK293/pcDNA3.1 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrsTWM2OD1zLkS1JOKyKDBwMkCgcm0> NH7rXnczPDd{NkezPS=>
HEK293/ABCC1 NX3YT243T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXYfVZKSzVyPUG5MlI6KMLzIEKuNFghdk1? MlPKNlQ4OjZ5M{m=
TCC M{ftbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLKSZkzPCCq MWXJR|UxRTdyIH7N MkLBNlQ4OTZ7NES=
TCC NH\0O2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rneVQ5KGh? MmnXTWM2OD13MDDuUS=> NF3v[JQzPDdzNkm0OC=>
HepG2/ADM M{LDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHqTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? Ml\sNlQ4ODR3NU[=
HepG2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEGxOeKyOC5yMEG3JO69VQ>? MWiyOFcxPDV3Nh?=
MCF-7/ADR M3v0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XsZ2lEPTB;ND60PFI3yrFyLkKwO|Ah|ryP M4rEVFI1PzB2NUW2
MCF-7 M1KzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjuOnl3UUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= NF7DRY0zPDdyNEW1Oi=>
A-172  NEm5co9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS1U5M4OC5zwrFOwG0> NH7ES48zPC95MjDo M2X0SYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> Mn20NlQ2OzB{M{W=
U-251MG NUnPcmc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMlHDqM7:TR?= MoLUNlQwPzJiaB?= NYnKfYVWcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NFnVUHgzPDV|MEKzOS=>
DLD-1 Ml3ySpVv[3Srb36gRZN{[Xl? MWixNFAhdk1? M4HqfVQ5KGh? M2nUdZBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? M3:5e|I1PDB|NEWz
CCD18Co MX\GeY5kfGmxbjDBd5NigQ>? M{L0U|ExOCCwTR?= NFzndYo1QCCq Mmm2dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh NF7iSm0zPDRyM{S1Ny=>
DLD-1 NV;yVHoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqwMVExODBibl2= NUPJboxZPDhiaB?= NYXMOVZocW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVKyOFQxOzR3Mx?=
CCD18Co Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDMVW1IOC1zMECwJI5O MmHjOFghcA>? MnvKbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NHnyNGwzPDRyM{S1Ny=>
HepG2 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\vd29UOjRiaB?= MkPPTWM2OD13Mj615qCK|ryP M3;MelI1OzRzNki4
HEK293/pcDNA3.1 NEfheIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEC0xtExNjByMEOg{txO M4jSdlI1Ojh2N{iz
HEK293/MRP1 NEHXTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXETWM2OD1yLkC1OeKyOC5yMUKwJO69VQ>? MW[yOFI5PDd6Mx?=
Ramos MYDBdI9xfG:|aYOgRZN{[Xl? MmroNwKBkc7:TR?= NEmxVlI1QCCq Ml7qbY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{ M{PMUFI1OjV4NEmx
NCI-H1299/pcDNA3 MkmyR4VtdCCYaXHibYxqfHliQYPzZZk> M4TMWlAuOjBibl2= M2[0[lk3KGh? MUXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M33NeFI1OTd5MEGy
H1299/ICAM-3 NEC5cXlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlG2NE0zOCCwTR?= MlPwPVYhcA>? MkG5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NVzHRYZ4OjRzN{ewNVI>
NCI-H1299/pcDNA3 NXzVUGhLTnWwY4Tpc44hSXO|YYm= MkDmNU82NzFyL{KwxsBvVQ>? NG\hfXA6PiCq NVjMPWhXcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? MneyNlQyPzdyMUK=
H1299/ICAM-3 Mkf3SpVv[3Srb36gRZN{[Xl? NG\KSXUyNzVxMUCvNlDDqG6P NF\pTFY6PiCq MkC2bY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> M1XORlI1OTd5MEGy
W1 NI\meGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HEe2lEPTB;MD6wNFMzKM7:TR?= MV6yOFE1ODF5Nh?=
W1VR NYrUSoFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrVTWM2OD1yLkC1OkDPxE1? MnL1NlQyPDBzN{[=
K562 M{W2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzHTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP MlHaNlQyOzV7M{e=
K562/ADR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjCWZRKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?= MX:yOFE{PTl|Nx?=
K562 MmLjRZBweHSxc3nzJGF{e2G7 NGTFW|QxNjNizszN NFfqSmUzPCCq M2rNTYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MV:yOFE{PTl|Nx?=
K562/ADR NYTs[WE5SXCxcITvd4l{KEG|c3H5 MVizJO69VQ>? MkPZNlQhcA>? MX7pcoR2[2W|IHHwc5B1d3Orcx?= NWH2eIZ{OjRzM{W5N|c>
A549 NYexSnpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnviTWM2OD1yLkGwJOKyKDBwMEOg{txO NYTQUXdyOjN7N{GwO|U>
K562 NVHYc3RZS2WubDDWbYFjcWyrdImgRZN{[Xl? MkC5N{44PeLCk{[wxsBvVQ>? MY[3NuKhcMLi NXHPdVJUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NYrMdnRTOjN6N{eyNlM>
lucena NGHiPFBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnTYN{44PeLCk{[wxsBvVQ>? M37VRVczyqCqwrC= MU\uc{Bm\m[nY4S= NV\SfnlGOjN6N{eyNlM>
FEPS Mny2R4VtdCCYaXHibYxqfHliQYPzZZk> MnL3N{44PeLCk{[wxsBvVQ>? MlHJO|LDqGkEoB?= NXfNZ5N5dm9iZX\m[YN1 MWCyN|g4PzJ{Mx?=
A2780 NX7mUnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwNTDtUS=> MlH0NlM5Ojl{MEO=
ACHN M3\nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRDBwMTDtUS=> MmDTNlM5Ojl{MEO=
U-937 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRDN2IH7N MonINlM5Ojl{MEO=
Jurkat M363[2Fxd3C2b4Ppd{BCe3OjeR?= NHHnT3Y2yqEQvHevcYzDqA>? NELoemUzPCCq NFjZSWtqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M4fSOVI{QDFyNEC5
Jurkat MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zYeVXDqM7:Zz;tcOKh MXSyOEBp NX\DdIN5[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl NVW0SXY{OjN6MUC0NFk>
Hep-2 NUPlSVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHUflFpUUN3ME2wMlA1yrFyLkCxJO69VQ>? NXHhOmk4OjN5OEC0NlQ>
Hep-2/v MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPPVVhHUUN3ME2xMljDuTBwMkCg{txO M{fTcFI{PzhyNEK0
SGC-7901 NIX5[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj0NE0yOCEQvHevcYw> M1W2bVI1NzR6L{eyJIg> MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NH3MVpEzOzd2M{W3Ni=>
SGC-7901/VCR M1X0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli0NE0yOCEQvHevcYw> MkGyNlQwPDhxN{KgbC=> M4T3dolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NYW4WGJPOjN5NEO1O|I>
SGC-7901 MVPBdI9xfG:|aYOgRZN{[Xl? MWPpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NILPNZYzOzd2M{W3Ni=>
SGC-7901/VCR MVnBdI9xfG:|aYOgRZN{[Xl? MWfpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NYDH[HFYOjN5NEO1O|I>
KB-3-1 NHzJdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nvT2lEPTB;MT62OkDDuSByLkG2NkDPxE1? NFPXR2wzOzZ5M{S0OS=>
KB-C2 NVj1bWZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJyMj61OkDDuSB2Mj60PFEh|ryP NFfiVo4zOzZ5M{S0OS=>
KB-3-1 NH\KXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwMk[gxtEhOC5yMkeg{txO NGDldJgzOzZ5M{S0OS=>
KB-V1 M4LaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf3fXNwUUN3ME2yNFgvQDViwsGgNlAvPCEQvF2= MmrSNlM3PzN2NEW=
HEK293/pcDNA3.1 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjLU3pKSzVyPUK0MlEhyrFiMD6yNFQh|ryP NIG0SoszOzZ5M{S0OS=>
HEK293/ABCB1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP6TWM2OD1|NUGyMlghyrFiM{e4MlM6OSEQvF2= M2O1[FI{Pjd|NES1
A549/EGFP  NVfNdnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjkem4xNjBzLUGwNFAh|ryP Mn:3TWM2OD16Nj63JOKyKDJ7LkGg{txO MVWyN|Y{PDJ6Mh?=
A549/Slug NHWxeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[wMlAyNTFyMECg{txO Ml\sTWM2OD17LkegxtEhOy5zIN88US=> NX;4UpF3OjN4M{SyPFI>
JFCR39  MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxJOK2VQ>? NFzoNXEzPCCq M1LkZmROW09? MVrtZZJs\WSueTDpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{ MmLaNlM2QTh{N{[=
A549 MUjGeY5kfGmxbjDBd5NigQ>? NGXBeHUyODBibl2= Mn3YNVYhcA>? MWfEUXNQ NWjwNlJFdGWjZIOgeI8h[SCub4PzJI9nKG2rY4LveJVjfWyncx?= MVyyN|U6QDJ5Nh?=
SGC7901 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T0W2lEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> M{\2S|I{PTZ2NEiy
SGC7901/LV-NC NVnzSm1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELITmJKSzVyPUGuO|fjiIoEsfMAjVAvOTZizsznM41t MUmyN|U3PDR6Mh?=
SGC7901/LV-SGO1 NIXOU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XPfWlEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw> NXzGSJRkOjN3NkS0PFI>
SGC7901/VCR MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzZTWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw> M3\xeFI{PTZ2NEiy
SGC7901/VCR-NC MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvUOoFKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>? M2HDbVI{PTZ2NEiy
SGC7901/VCR-si-SGO1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjq[5ZKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t MlGzNlM2PjR2OEK=
SGC7901/ADR M{LPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfaTWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=> M1H4NFI{PTZ2NEiy
SGC7901/ADR-NC NEO5emhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPQPYJKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t MlTVNlM2PjR2OEK=
SGC7901/ADR-si-SGO1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;He3RKSzVyPUOuOFbjiIoEsfMAjVAvOjlizsznM41t Mkj1NlM2PjR2OEK=
SH-SY5Y  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvuNE4xODFvMUCg{txO M1ziT|I1KGh? NF;C[odKSzVyPUCuNVE{yrFyLkCxNkDPxE1? MUGyN|EzQTB4NR?=
SH-SY5Y  MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDXOYExNjByMT2xNEDPxE1? M1jjTFQ5KGh? MkSyTWM2OD1yLkC3POKyOC5yMEmg{txO M17XU|I{OTJ7ME[1
SH-SY5Y  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTkR5UxNjByMT2xNEDPxE1? M1izW|czKGh? M4HaVmlEPTB;MD6wOVHDuTBwMEC4JO69VQ>? NYDXfot6OjNzMkmwOlU>
SH-SY5Y M{\5VGFxd3C2b4Ppd{BCe3OjeR?= MlmwNE4yKM7:TR?= NWDGOJhnOC1{NDDo MnTEbY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= MXSyN|EzQTB4NR?=
SH-SY5Y NF6ybWNCeG:ydH;zbZMhSXO|YYm= NEHTTVQxNjFizszN NHzUVYQxNTJ2IHi= MXrpcoR2[2W|IH3peI91cWNiYYLy[ZN1yqB? MlOwNlMyOjlyNkW=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID